This is consistent with published data showing that preclinically the combination of type II RAF inhibitors and MEK inhibitors is synergistic in colorectal, melanoma, and lung tumor cell lines with mutations in NF1, BRAF, or KRAS (27, 40, 41). Here, KRAS is linked to melanoma.